Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536030 | 0.86 | L3MBTL1 (0.54) | CYP2C19METMEN1HTTKMT2A | |
| SCHEMBL29605111 | 0.86 | L3MBTL1 (0.54) | CYP2C19METMEN1HTTKMT2A | |
| SCHEMBL1536117 | 0.83 | ALDH1A1 (0.42) | CYP2C19METMEN1HTTKMT2A | |
| SCHEMBL28017834 | 0.81 | RAPGEF4 (0.43) | CYP2C19METHTR6HTTALDH1A1 | |
| SCHEMBL31069825 | 0.80 | HPGD (0.39) | CYP2C19METMEN1HTTKMT2A | |
| SCHEMBL31441372 | 0.80 | HPGD (0.39) | CYP2C19METMEN1HTTKMT2A | |
| SCHEMBL12032300 | 0.79 | MAPK1 (0.34) | METHTR6L3MBTL1CCR4 | |
| SCHEMBL21295073 | 0.77 | MET (0.65) | CYP2C19METHTR6MEN1HTT | |
| SCHEMBL29847193 | 0.77 | MET (0.65) | CYP2C19METHTR6MEN1HTT | |
| SCHEMBL1359397 | 0.77 | CYP2C19 (0.61) | CYP2C19METHTR6MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4067347-A1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388185-B2 | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2924038-A1 | Preparation of pyrrolo[2,3-b]pyrazine and pyrrolo[2,3-b]pyridine derivatives as FGFR inhibitors | Evotec (UK) Ltd. (GB) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014026125-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014004863-A2 | COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | CYP2C19 3164/4885MET 2923/4885HTR6 2527/4885 |
| US-20160280713-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | CYP2C19 855/4885MET 20/4885HTR6 3626/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CYP2C19 3059/4885MET 2924/4885HTR6 2639/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CYP2C19 3059/4885MET 2924/4885HTR6 2639/4885 |
| US-20140045814-A1 | PYRAZINE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR2, FGFR3 | CYP2C19 855/4885MET 20/4885HTR6 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.